Erratum: Better living through microbes

Monya Baker

Nat. Biotechnol. 23, 645–647 (2005)

On page 646, Table 1, last column, the status of the Osel bacteriotherapy *Clostridium butyricum* was given as “Phase 2 trial.” It should have read, “Phase 2/3 trial (US) planned.”

On page 647, column 2, last paragraph, line 16, “...a tumor marker present in many ovarian and prostate cancers...” should have read “a tumor marker present in many ovarian and pancreatic cancers...” Prostate cancers should have been pancreatic cancers. In the last line of the same paragraph, “EphsA2 antigen” should have been “EphA2 antigen.”

Erratum: Leaders and laggards in the stem cell enterprise

Stephan Herrera

Nat. Biotechnol. 23, 775–777 (2005)

On page 776, column 3, paragraph 3, line 8, one of the recipients of the Starr Foundation gift for stem cell research was reported to be Rochester University; it should have read Rockefeller University.

Corrigendum: The origins of new drugs

Robert Kneller

Nat. Biotechnol. 23, 529–530 (2005)

On page 528, an imaging agent, Prussian Blue, was mistakenly included in the NME totals for 2003. Thus, in Table 1 and corresponding places in the text, the total number of NMEs approved in 2003 should be reduced from 21 to 20 and the total number of new drugs from 27 to 26. The totals for the 6-year period should be similarly reduced from 145 to 144 for total NMEs and from 171 to 170 for total drugs. Also, the NME Somavert originated in Ohio University, which then licensed rights to Genentech. Thus, the number of university inventions should be increased from 3 to 4 for 2003, and from 20 to 21 for the entire 6-year period.

Corrigendum: National origins of new drugs

Robert Kneller

Nat. Biotechnol. 23, 655–656 (2005)

On page 655, in calculating the nonpharma portion of NMEs in Table 1, errors arose because in the case of two of the drugs that were attributed to multiple countries, a fractional value for one country was not included in the nonpharma totals. Thus, the US NME nonpharma contribution, reported as 32.8 (56%), should have read 33.0 (56%); the Swiss NME nonpharma contribution, reported as 1.3 (13%), should have read 1.0 (10%); and the total nonpharma contribution, reported as 47.8 (33%), should have read 47.7 (33%).